Frank L. Van de Veerdonk, M tadora.org .D., Ph.D., Theo S. Plantinga, Ph.D., Alexander Hoischen, Ph.D., Sanne P. Smeekens, M.Sc., Leo A.B. Joosten, Ph.D., Christian Gilissen, Ph.D., Peer Arts, Ph.D., Diana C. Rosentul, M.Sc., Andrew J. Carmichael, M.D., Chantal A.A. Smits-van der Graaf, M.D., Ph.D., Bart Jan Kullberg, M.D., Ph.D., Jos W.M. Van der Meer, M.D., Ph.D., Desa Lilic, M.D., Ph.D., Joris A. Veltman, Ph.D., and Mihai G. Netea, M.D., Ph.D.: STAT1 Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis Chronic mucocutaneous candidiasis is a primary immunodeficiency disorder that’s seen as a susceptibility to infection of the skin, nails, and mucous membranes by candida species and dermatophytes.1 There are many CMC subtypes: autosomal recessive autoimmune polyendocrinopathy candidiasis with ectodermal dystrophy , autosomal dominant CMC with or without thyroid disease, and autosomal recessive, isolated CMC.
The study focused on what’s known as ductal carcinoma in situ – – an extremely early stage of breasts cancer that indicates the current presence of noninvasive, yet potentially early cancer cells. With this evaluation, we sought to determine what treatment women selected when diagnosed with [ductal carcinoma in situ], and whether there is any impact in mortality with the different treatments, said study senior author Dr. Shelley Hwang, chief of breast surgery at Duke Malignancy Institute in Durham, N.C. The researchers analyzed data from more than 121,000 cases of ductal carcinoma in situ diagnosed nationwide between 1991 and 2010. In general, less aggressive treatment became more prevalent during the scholarly research period.